When it comes to the FDA approval process, Office of New Drugs director John Jenkins wants to make one thing very clear. All those external analyses that FDA is more conservative in its approval standards than its European regulatory counterpart are misguided and largely overblown.
During a keynote presentation at FDC-Windhover’s FDA/CMS Summit for Biopharma Executives on December 4, Jenkins acknowledged recent criticism from analysts...




